<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Heliyon</journal-id><journal-id journal-id-type="iso-abbrev">Heliyon</journal-id><journal-id journal-id-type="pmc-domain-id">2992</journal-id><journal-id journal-id-type="pmc-domain">heliyon</journal-id><journal-title-group><journal-title>Heliyon</journal-title></journal-title-group><issn pub-type="epub">2405-8440</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10981064</article-id><article-id pub-id-type="pmcid-ver">PMC10981064.1</article-id><article-id pub-id-type="pmcaid">10981064</article-id><article-id pub-id-type="pmcaiid">10981064</article-id><article-id pub-id-type="pmid">38560203</article-id><article-id pub-id-type="doi">10.1016/j.heliyon.2024.e28285</article-id><article-id pub-id-type="pii">S2405-8440(24)04316-0</article-id><article-id pub-id-type="publisher-id">e28285</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Lung adenocarcinoma patients with <italic toggle="yes">ROS1</italic>-rearranged tumors by sex and smoking intensity</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Peng</surname><given-names initials="Y">Yanmei</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Ernani</surname><given-names initials="V">Vinicius</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Liu</surname><given-names initials="D">Dan</given-names></name><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Guo</surname><given-names initials="Q">Qian</given-names></name><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Hopps</surname><given-names initials="M">Markay</given-names></name><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Cappelleri</surname><given-names initials="JC">Joseph C.</given-names></name><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Gupta</surname><given-names initials="R">Ruchi</given-names></name><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>de Andrade</surname><given-names initials="M">Mariza</given-names></name><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Chen</surname><given-names initials="J">Jun</given-names></name><xref rid="aff9" ref-type="aff">i</xref><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Yi</surname><given-names initials="ES">Eunhee S.</given-names></name><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Yang</surname><given-names initials="P">Ping</given-names></name><email>Yang.Ping@mayo.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1"><label>a</label>Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, AZ, 85259, USA</aff><aff id="aff2"><label>b</label>Department of Oncology, Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, 102400, China</aff><aff id="aff3"><label>c</label>Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, AZ, 85054, USA</aff><aff id="aff4"><label>d</label>Division of Pulmonary &amp; Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610064, China</aff><aff id="aff5"><label>e</label>Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital &amp; Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610041, China</aff><aff id="aff6"><label>f</label>Vaccine R&amp;D, Pfizer Inc, New York, NY, 10017, USA</aff><aff id="aff7"><label>g</label>Executive Director of Biostatistics, Pfizer Inc, Groton, CT, 06340, USA</aff><aff id="aff8"><label>h</label>Division of Biostatistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA</aff><aff id="aff9"><label>i</label>The Second Affiliated Hospital of Dalian Medical University, Shahekou District, Dalian, 116023, China</aff><aff id="aff10"><label>j</label>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>Yang.Ping@mayo.edu</email></corresp><fn id="fn1"><label>1</label><p id="ntpara0010">Yanmei Peng, Vinicius Ernani and Dan Liu contributed equally.</p></fn></author-notes><pub-date pub-type="collection"><day>15</day><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>16</day><month>3</month><year>2024</year></pub-date><volume>10</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">458849</issue-id><elocation-id>e28285</elocation-id><history><date date-type="received"><day>29</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>14</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>30</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-02 12:25:23.027"><day>02</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 Published by Elsevier Ltd.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Background</title><p><italic toggle="yes">ROS1</italic> rearrangements (<italic toggle="yes">ROS1</italic>+) define a distinct molecular subset of lung adenocarcinomas. <italic toggle="yes">ROS1</italic> + tumors are known to occur more in never-smokers, but the frequency and outcome of <italic toggle="yes">ROS1</italic> positivity by sex and smoking intensity are not clearly documented.</p></sec><sec><title>Patients and methods</title><p>This patient cohort study included all never- (&lt;100 cigarettes lifetime) and light- (100 cigarettes-20 pack-years) smokers, and a sample of heavy-smokers. <italic toggle="yes">ROS1</italic> + rates by sex and smoking intensity were compared within and beyond our study. Survival outcomes were analyzed using Kaplan-Meier curves and Cox proportional hazards models.</p></sec><sec><title>Results</title><p>Of the 571 total patients, <italic toggle="yes">ROS1</italic> + was detected in 24 (4.2%): 6.4% in men and 3.0% in women; 5.1% in never-, 5.7% in light-, and 1.8% in heavy-smokers (<italic toggle="yes">P</italic>=0.05). Among the 209 stage IIIB-IV patients, men had much higher <italic toggle="yes">ROS1</italic> + rate (11.1%) not only than women (1.7%, <italic toggle="yes">P</italic>=0.004) in our study, but also than men (0.4%&#8211;1.8%) in 8 published studies (<italic toggle="yes">Ps</italic>&#160;=&#160;0.0019&#8211;0.0001). <italic toggle="yes">ROS1</italic>+ rates were similar between never- (9.3%) and light-smokers (8.1%) and significantly lower in heavy-smokers (1.2%, <italic toggle="yes">P</italic>=0.017), a finding confirmed by 6 published studies (<italic toggle="yes">Ps</italic>&#160;=&#160;0.041&#8211;0.0001). Overall survival of <italic toggle="yes">ROS1</italic> + patients were significantly better than the <italic toggle="yes">ROS1-</italic> (<italic toggle="yes">P</italic>=0.023) mainly due to targeted therapy. Among patients who exhibited resistance to crizotinib, follow-up treatment of entrectinib and lorlatinib showed remarkable survival benefits.</p></sec><sec><title>Conclusions</title><p>The <italic toggle="yes">ROS1</italic> + rates were higher in men than in women, and similar in never- and light-smokers, more pronounced in stage IIIB-IV patients. Newer-generation <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted drugs showed efficacy in a cohort of crizotinib resistant <italic toggle="yes">ROS1</italic> + patients. These results, when validated, could assist efficiently accruing <italic toggle="yes">ROS1</italic> + patients.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Lung adenocarcinoma</kwd><kwd><italic toggle="yes">ROS1</italic></kwd><kwd>Sex</kwd><kwd>Smoking intensity</kwd><kwd>Survival</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">The incidence and mortality of lung cancer have been decreasing; however, it remains the primary cause of cancer-related deaths in the United States [<xref rid="bib1" ref-type="bibr">1</xref>]. Most patients are diagnosed with metastatic disease and have a 5-year survival rate of approximately 7% [<xref rid="bib1" ref-type="bibr">1</xref>]. There have been major advancements in the diagnosis and treatment of advanced non-small cell lung cancer (NSCLC), with one of the most important developments being the characterization of key molecular alterations that drive lung carcinogenesis in a subset of NSCLC. Previous reports suggested that <italic toggle="yes">c-ros oncogene 1</italic> (<italic toggle="yes">ROS1</italic>) rearrangements occurred in 0.9%&#8211;1.7% NSCLC patients [<xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>] and 1.3%&#8211;2.8% advanced-stage patients [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib7" ref-type="bibr">7</xref>].</p><p id="p0015"><italic toggle="yes">ROS1</italic> is a receptor of tyrosine kinase of the insulin receptor family and has been identified as a driver gene of NSCLC patients [<xref rid="bib2" ref-type="bibr">2</xref>]<italic toggle="yes">. ROS1</italic> rearrangements (<italic toggle="yes">ROS1</italic>+) tumors are usually associated with younger age, no smoking history, and adenocarcinomas, and appear a similar frequency in men and women [<xref rid="bib2" ref-type="bibr">2</xref>]. Genomics Evidence Neoplasia Information Exchange project (GENIE) showed alike <italic toggle="yes">ROS1</italic> + rates in men and women among NSCLC patients [<xref rid="bib8" ref-type="bibr">8</xref>] while other studies found <italic toggle="yes">ROS1</italic> + rates tended to be prevalent in women [<xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>]. The first study by Bergethon and colleagues did not give a clear definition for &#8220;light-smoker&#8221; that could be differentiated from other smokers regarding <italic toggle="yes">ROS1</italic> + rate [<xref rid="bib2" ref-type="bibr">2</xref>]; GENIE defined light-smokers as 1&#8211;15 pack-years (py) smoking history with <italic toggle="yes">ROS1</italic> + rate at 0.9%, higher than the heavy-smokers as more than 15py (0.08%, <italic toggle="yes">P</italic>=0.0057) [<xref rid="bib8" ref-type="bibr">8</xref>]. In a recent real-world population-based study from the Netherlands [<xref rid="bib12" ref-type="bibr">12</xref>], the prevalence of <italic toggle="yes">ROS1</italic> + was 0.43% among stage-IV NSCLC patients, without information on smoking history.</p><p id="p0020">In 2016, crizotinib was the first tyrosine kinase inhibitor (TKI) approved by the U.S. Food and Drug Administration (FDA) for <italic toggle="yes">ROS1</italic> + NSCLC based on PROFILE 1001 study [<xref rid="bib13" ref-type="bibr">13</xref>]; entrectinib was approved later [<xref rid="bib14" ref-type="bibr">14</xref>] and lorlatinib was the newest treatment option [<xref rid="bib15" ref-type="bibr">15</xref>]. The response to targeted therapy and progression-free survival (PFS) for <italic toggle="yes">ROS1</italic> + NSCLC have improved much with median time to progression of 5.5&#8211;20 months [<xref rid="bib16" ref-type="bibr">16</xref>].</p><p id="p0025">Although <italic toggle="yes">epidermal growth factor receptor</italic> (<italic toggle="yes">EGFR</italic>) gene mutated proportionally more in women than in men [<xref rid="bib17" ref-type="bibr">17</xref>], the variation of <italic toggle="yes">ROS1</italic> + by sex is still inconclusive. Given the higher incidence of <italic toggle="yes">ROS1</italic> + in never-smokers, the PROFILE 1001 study included a very small population of smokers and former smokers [<xref rid="bib13" ref-type="bibr">13</xref>], and the distribution of <italic toggle="yes">ROS1</italic> + tumors among patients with different smoking intensity was unavailable. We hypothesized that the distribution of <italic toggle="yes">ROS1</italic>+ tumors varied by sex and smoking status in real-world patients, especially in never- and light-smokers. Therefore, we conducted an observational cohort study combined with a comparison of our findings with the published literature to further elucidate the rate of <italic toggle="yes">ROS1</italic> + according to sex and smoking intensity.</p></sec><sec id="sec2"><label>2</label><title>Methods</title><sec id="sec2.1"><label>2.1</label><title>Patient population</title><p id="p0030">Patients were enrolled from the Mayo Clinic Lung Cancer Cohort, which included approximately 17,000 newly diagnosed primary lung cancer patients between 1997 and 2015. Detailed procedures of patient enrollment, diagnosis, data collection, and follow-up have been previously described [<xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib20" ref-type="bibr">[20]</xref>]; the study was approved by the Mayo Foundation Institutional Review Board (IRB# 225-9). Briefly, pathologic diagnoses of primary lung cancer for the study cohort were made at Mayo Clinic, where all patients were treated, prospectively enrolled, and followed through 2022.</p><p id="p0035">The evaluated cohort consisted of patients with an adenocarcinoma according to the World Health Organization (WHO) classification [<xref rid="bib21" ref-type="bibr">21</xref>]. All patients who had available slides or tumor tissue for pathologic review were screened and categorized into light-, never- and heavy-smokers. The design was to maximize patients with <italic toggle="yes">ROS1</italic> + in never- and light-smokers, with a random sample of heavy-smokers as a comparator; total sample size was restricted by funding limit. The cigarette smoking intensity was classified by self-report smoking history at the time of diagnosis recorded in patient medical records: never-smokers (none to fewer than 100 cigarettes during their lifetime), light-smokers (100 cigarettes-20py), or moderate-heavy smokers (&gt;20py, abbreviated as heavy-smokers in this study).</p></sec><sec id="sec2.2"><label>2.2</label><title><italic toggle="yes">ROS1</italic> diagnosis and co-occurring mutations</title><p id="p0040"><italic toggle="yes">ROS1</italic> + was detected using a laboratory-developed dual-color break-apart probe (Vysis; Abbott Molecular, Abbott Park, IL) [<xref rid="bib22" ref-type="bibr">22</xref>]. Hematoxylin and eosin (HE)-staining was performed on 5-&#956;m sections. Using HE slide as a reference; target areas were etched with a diamond-tipped etcher on the back of the unstained slide to be assayed by a pathologist. Each probe was hybridized to the appropriate target area and 2 technologists each analyzed 50 interphase nuclei (100 total) with the results recorded as percentage of abnormal nuclei. The probe set was independently validated in a blinded study on 20 paraffin-embedded lung adenocarcinoma tissue samples and 25 noncancerous controls. <italic toggle="yes">ROS1</italic> + was verified in samples previously identified using reverse-transcriptase-polymerase-chain reaction. Normal controls were used to determine a cutoff value for this assay.</p><p id="p0045">Fluorescence in situ hybridization (FISH) analysis of rearrangement was performed on cytology or tissue samples using probes for 3&#8242; and 5&#8242; regions of the <italic toggle="yes">ROS1</italic> gene at 6q22 in 100 nuclei [<xref rid="bib3" ref-type="bibr">3</xref>]. FISH scoring was performed by experienced technicians in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, and the results were reviewed by expert pathologists. According to the ratios of separated signals, FISH results were dichotomized into <italic toggle="yes">ROS1</italic> + and <italic toggle="yes">ROS1</italic>-. Cases with either &gt;9% of the tumor cells showing an isolated 3&#8242; signal or &gt;5% of the tumor cells showing an isolated 3&#8242; signal plus other types of isolated signals in &gt;3% of the tumor cells were ruled as <italic toggle="yes">ROS1</italic>+; all other cases were considered <italic toggle="yes">ROS1</italic> negative (<italic toggle="yes">ROS1</italic>-). The 3&#8242; signal was used, since the kinase domain is theoretically within this region, and if lost, there likely is no kinase domain; an isolated 5&#8242; domain is clinically equivocal.</p><p id="p0050">The co<bold>-</bold>occurring mutations of <italic toggle="yes">EGFR</italic> and <italic toggle="yes">ALK</italic> were detected when the patients were diagnosed with lung adenocarcinoma by pathologists. A polymerase chain reaction (PCR) based assay employing allele specific amplification was used to test for the presence of 29 mutations within exons 18&#8211;21 of the <italic toggle="yes">EGFR</italic> gene (G719A, G719S, G719C in exon 18; small deletions in exon 19; T790&#160;M, S768I, and small insertions in exon 20; and L858R and L861Q in exon 21). FISH was used for testing rearrangement of the <italic toggle="yes">ALK</italic> gene locus using FDA approved probe kit for the 3&#8242; and 5&#8242; regions of the <italic toggle="yes">ALK</italic> gene at 2p23 in 50 nuclei.</p></sec><sec id="sec2.3"><label>2.3</label><title>Data extraction and outcomes</title><p id="p0055">Data retrospectively collected on identified patients included clinical characteristics, tobacco consumption, outcomes, and all information on therapeutic strategies. Clinicopathologic stage was assigned according to the seventh edition of the TNM staging system [<xref rid="bib23" ref-type="bibr">23</xref>], which was published in 2009. In TNM system, the letter T refers to size and extent of the main tumor, usually called primary tumor; the letter N represents the number and location of regional lymph nodes involvement; the letter M represents distant metastasis [<xref rid="bib24" ref-type="bibr">24</xref>]. Responses were defined as the best response from the start of treatment until disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) guidelines version 1.1 [<xref rid="bib25" ref-type="bibr">25</xref>]. Overall response rate (ORR) was defined as the proportion of patients who achieved a complete response (CR) or partial response (PR). The disease control rate (DCR) was defined as the proportion of patients with a best overall response of CR, PR or stable disease (SD); CR, PR, and SD were defined in accordance with RECIST [<xref rid="bib25" ref-type="bibr">25</xref>].</p><p id="p0060">Annual verification of patients' vital status was accomplished through the Mayo Clinic's electronic medical notes and registration database, next-of-kin reports, death certificates, and obituary documents filed in the patient's medical records, as well as through the Mayo Clinic Tumor Registry and Social Security Death Index website. Follow-up was used for determination of OS, defined as the time from diagnosis to date of last follow-up or patient death, and disease-free survival (DFS), defined as the time from diagnosis to tumor recurrence, progression, or death from lung cancer. Data on these events were collected in a prospective manner during follow-up that was up to 20 years from the date of diagnosis.</p></sec><sec id="sec2.4"><label>2.4</label><title>Literature review and comparison</title><p id="p0065">Published literature from 2007 to 2023 was searched and retrieved from PubMed with a strategy of (&#8220;ros1"[All Fields] AND (&#8220;sex"[MeSH Terms] OR &#8220;sex"[All Fields])) OR (&#8220;ros1"[All Fields] AND (&#8220;smoke"[MeSH Terms] OR &#8220;smoke"[All Fields] OR &#8220;smoked"[All Fields] OR &#8220;smokes"[All Fields] OR &#8220;smoking"[MeSH Terms] OR &#8220;smoking"[All Fields] OR &#8220;smokings"[All Fields])). Three inclusion criteria for eligible articles were as follows: (a) observational studies for NSCLC in real-world setting or cohort; (b) <italic toggle="yes">ROS1</italic> status among sex or smoking history was involved; and (c) race of the participants was comparable to our study. Studies specifically on Asian population, case reports and guidelines of <italic toggle="yes">ROS1</italic> + in NSCLC were excluded. <italic toggle="yes">ROS1</italic> + rates by sex and smoking intensity, measured as pack-years, were compared within our study sample and to what were reported in studies selected from the online search.</p></sec><sec id="sec2.5"><label>2.5</label><title>Statistical analysis</title><p id="p0070">Descriptive statistics characterized means and proportions, and <italic toggle="yes">t</italic>-test and Fisher's exact test were used to evaluate proportions for sparse data [<xref rid="bib26" ref-type="bibr">26</xref>]. Kaplan-Meier survival analysis was used to evaluate OS and DFS, with comparisons performed using log-rank tests [<xref rid="bib27" ref-type="bibr">27</xref>]. Patients still alive at the last visit were censored at the date of last follow-up, as were patients without documented evidence of an event. To evaluate the independent role of each variable on survival outcome, univariate and multivariate Cox proportional hazards (CoxPH) models were applied separately for OS and DFS [<xref rid="bib27" ref-type="bibr">27</xref>]; one model adjusted for age, sex, smoking status, and treatment (drug or drug-related therapy, surgery and drug with/without radiation, surgery only or other therapy), while the other model adjusted for smoking status and <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted drug (yes&#160;=&#160;crizotinib or ceritinib, no&#160;=&#160;no such drug), with results expressed as hazard ratios (HR) and 95% confidence intervals (95% CI). <italic toggle="yes">P</italic>-values &lt;0.05 were considered statistically significant. The descriptive and Kaplan-Meyer analyses were performed using SAS version 9.0 (SAS Institute, Cary, NC) and for the CoxPH models, the survival R package for the CoxPH Models was applied [<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib29" ref-type="bibr">29</xref>]. The CoxPH curves were truncated at 10 years for all patients and, separately at 5 years for stage IIIB-IV patients, adjusting for the smoking history, treatment, and sex.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Frequency and clinical characteristics of the patients in the study</title><p id="p0075">Among a total of 571 patients with adenocarcinoma, 203 (35.6%) were men and 368 (64.4%) women; 334 (59%) were never smokers, 70 (12%) light and 167 (29%) heavy smokers. <italic toggle="yes">ROS1</italic> + tumors were identified in 24 (4.2%) patients; mean (&#177;SD) age at diagnosis of <italic toggle="yes">ROS1</italic> + patients were 58.4 (&#177;13.5), significantly younger than the <italic toggle="yes">ROS1-</italic> patients at 66.4 (&#177;11.4) years. More detailed information of all stage patients was provided in <xref rid="tbl1" ref-type="table">Table 1</xref>. There was no significant difference in tumor grade and stage between <italic toggle="yes">ROS1</italic> + and <italic toggle="yes">ROS1-</italic> groups. <xref rid="tbl2" ref-type="table">Table 2</xref> described the 209 patients diagnosed with stage IIIB-IV disease; 183 (87.6%) were stage IV and 12 (5.7%) were <italic toggle="yes">ROS1</italic>+. In addition to significant difference in age, <italic toggle="yes">ROS1</italic> + and <italic toggle="yes">ROS1</italic>- groups differed for receiving <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted therapies as expected.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Descriptive characteristics of the population.</p></caption><alt-text id="alttext0025">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Characteristic</th><th rowspan="2" colspan="1">Total (N&#160;=&#160;571)</th><th colspan="3" rowspan="1"><italic toggle="yes">ROS1</italic> status<hr/></th></tr><tr><th colspan="1" rowspan="1"><italic toggle="yes">ROS1</italic> + (n&#160;=&#160;24)</th><th colspan="1" rowspan="1"><italic toggle="yes">ROS1-</italic>(n&#160;=&#160;547)</th><th colspan="1" rowspan="1"><italic toggle="yes">P-</italic>value</th></tr></thead><tbody><tr><td colspan="5" align="left" rowspan="1">Age at diagnosis</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean (SD)</td><td align="left" colspan="1" rowspan="1">66.1 (11.5)</td><td align="left" colspan="1" rowspan="1">58.4 (13.5)</td><td align="left" colspan="1" rowspan="1">66.4 (11.4)</td><td align="left" colspan="1" rowspan="1"><bold>0.003</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (range)</td><td align="left" colspan="1" rowspan="1">68 (26&#8211;93)</td><td align="left" colspan="1" rowspan="1">60 (33&#8211;85)</td><td align="left" colspan="1" rowspan="1">68 (26&#8211;93)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Gender, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><bold>0.052</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td align="left" colspan="1" rowspan="1">203 (35.6)</td><td align="left" colspan="1" rowspan="1">13 (54.2)</td><td align="left" colspan="1" rowspan="1">190 (34.7)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Female</td><td align="left" colspan="1" rowspan="1">368 (64.4)</td><td align="left" colspan="1" rowspan="1">11 (45.8)</td><td align="left" colspan="1" rowspan="1">357 (65.3)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Race, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.000</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Caucasian</td><td align="left" colspan="1" rowspan="1">517 (90.5)</td><td align="left" colspan="1" rowspan="1">22 (91.7)</td><td align="left" colspan="1" rowspan="1">495 (90.5)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other</td><td align="left" colspan="1" rowspan="1">54 (9.5)</td><td align="left" colspan="1" rowspan="1">2 (8.3)</td><td align="left" colspan="1" rowspan="1">52 (9.5)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cigarette smoking status, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.344</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Never</td><td align="left" colspan="1" rowspan="1">334 (58.5)</td><td align="left" colspan="1" rowspan="1">17 (70.8)</td><td align="left" colspan="1" rowspan="1">317 (58.0)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Former</td><td align="left" colspan="1" rowspan="1">140 (24.5)</td><td align="left" colspan="1" rowspan="1">3 (12.5)</td><td align="left" colspan="1" rowspan="1">137 (25.0)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Current</td><td align="left" colspan="1" rowspan="1">97 (17.0)</td><td align="left" colspan="1" rowspan="1">4 (16.7)</td><td align="left" colspan="1" rowspan="1">93 (17.0)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="4" align="left" rowspan="1">Smoking intensity among all smokers (n&#160;=&#160;237), n (%)</td><td align="left" colspan="1" rowspan="1">0.200</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Light (100 cigarettes-20 pack-years)</td><td align="left" colspan="1" rowspan="1">70 (29.5)</td><td align="left" colspan="1" rowspan="1">4 (57.1)</td><td align="left" colspan="1" rowspan="1">66 (28.7)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Heavy (&gt;20 pack-years)</td><td align="left" colspan="1" rowspan="1">167 (70.5)</td><td align="left" colspan="1" rowspan="1">3 (42.9)</td><td align="left" colspan="1" rowspan="1">164 (71.3)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoking Intensity (all patients)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.065</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Never-light (0&#8211;20 pack-years)</td><td align="left" colspan="1" rowspan="1">404 (70.8)</td><td align="left" colspan="1" rowspan="1">21 (87.5)</td><td align="left" colspan="1" rowspan="1">383 (70.0)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Heavy (&gt;20 pack-years)</td><td align="left" colspan="1" rowspan="1">167 (29.2)</td><td align="left" colspan="1" rowspan="1">3 (12.5)</td><td align="left" colspan="1" rowspan="1">164 (30.0)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Tumor grade, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.287</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Well</td><td align="left" colspan="1" rowspan="1">177 (31.0)</td><td align="left" colspan="1" rowspan="1">5 (20.8)</td><td align="left" colspan="1" rowspan="1">172 (31.4)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Moderate</td><td align="left" colspan="1" rowspan="1">192 (33.6)</td><td align="left" colspan="1" rowspan="1">7 (29.2)</td><td align="left" colspan="1" rowspan="1">185 (33.8)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Poor</td><td align="left" colspan="1" rowspan="1">202 (35.4)</td><td align="left" colspan="1" rowspan="1">12 (50.0)</td><td align="left" colspan="1" rowspan="1">190 (34.7)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Stage, n (%)<xref rid="tbl1fnc" ref-type="table-fn">c</xref></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.195</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;I</td><td align="left" colspan="1" rowspan="1">213 (37.3)</td><td align="left" colspan="1" rowspan="1">6 (25.0)</td><td align="left" colspan="1" rowspan="1">207 (37.8)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;II</td><td align="left" colspan="1" rowspan="1">59 (10.3)</td><td align="left" colspan="1" rowspan="1">1 (4.2)</td><td align="left" colspan="1" rowspan="1">58 (10.6)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;IIIA</td><td align="left" colspan="1" rowspan="1">90 (15.8)</td><td align="left" colspan="1" rowspan="1">5 (20.8)</td><td align="left" colspan="1" rowspan="1">85 (15.5)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;IIIB</td><td align="left" colspan="1" rowspan="1">26 (4.6)</td><td align="left" colspan="1" rowspan="1">3 (12.5)</td><td align="left" colspan="1" rowspan="1">23 (4.2)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;IV</td><td align="left" colspan="1" rowspan="1">183 (32.0)</td><td align="left" colspan="1" rowspan="1">9 (37.5)</td><td align="left" colspan="1" rowspan="1">174 (31.8)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">ALK</italic> rearrangement</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.445</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">13 (2.3)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">13 (2.4)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">558 (97.7)</td><td align="left" colspan="1" rowspan="1">24 (100)</td><td align="left" colspan="1" rowspan="1">534 (97.6)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">EGFR</italic> mutation, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.711</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">47 (8.2)</td><td align="left" colspan="1" rowspan="1">1 (4.2)</td><td align="left" colspan="1" rowspan="1">46 (8.4)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">524 (91.8)</td><td align="left" colspan="1" rowspan="1">23 (95.8)</td><td align="left" colspan="1" rowspan="1">501 (91.6)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Treatment<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.018</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Drug or drug-related therapy</td><td align="left" colspan="1" rowspan="1">170 (29.8)</td><td align="left" colspan="1" rowspan="1">12 (50.0)</td><td align="left" colspan="1" rowspan="1">158 (28.9)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Surgery and drug with/without radiation</td><td align="left" colspan="1" rowspan="1">124 (21.7)</td><td align="left" colspan="1" rowspan="1">7 (29.2)</td><td align="left" colspan="1" rowspan="1">117 (21.4)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Surgery only or other therapy</td><td align="left" colspan="1" rowspan="1">277 (48.5)</td><td align="left" colspan="1" rowspan="1">5 (20.8)</td><td align="left" colspan="1" rowspan="1">272 (49.7)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Targeted therapy<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><bold>&lt; 0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic> drug &#8211; Yes</td><td align="left" colspan="1" rowspan="1">20 (3.5)</td><td align="left" colspan="1" rowspan="1">9 (37.5)</td><td align="left" colspan="1" rowspan="1">11 (2.0)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic> drug &#8211; No</td><td align="left" colspan="1" rowspan="1">551 (96.5)</td><td align="left" colspan="1" rowspan="1">15 (62.5)</td><td align="left" colspan="1" rowspan="1">536 (98.0)</td><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0015">294 patients received drug therapy, including chemo-, targeted-, immune- and other pharmacologic agents; &#8220;other therapy&#8221; consisted of radiation only, surgery with adjuvant radiation, other treatment, and unspecified treatment.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0020">Targeted therapy included crizotinib or ceritinib.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnc"><label>c</label><p id="ntpara0025">Because of low number of patients, stages I&#160;+&#160;II and IIIA&#160;+&#160;IIIB were also combined, and not reach significance (<italic toggle="yes">P</italic>=0.128).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Descriptive Characteristics of Stage IIIB-IV patients (N&#160;=&#160;209).</p></caption><alt-text id="alttext0030">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Characteristic</th><th rowspan="2" colspan="1">Total, N&#160;=&#160;209</th><th colspan="3" rowspan="1"><italic toggle="yes">ROS1</italic> status<hr/></th></tr><tr><th colspan="1" rowspan="1"><italic toggle="yes">ROS1</italic>+</th><th colspan="1" rowspan="1"><italic toggle="yes">ROS1-</italic></th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">(n&#160;=&#160;12)</td><td align="left" colspan="1" rowspan="1">(n&#160;=&#160;197)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Age at diagnosis</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><bold>0.009</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean (SD)</td><td align="left" colspan="1" rowspan="1">63.4 (12.1)</td><td align="left" colspan="1" rowspan="1">53.3 (15.2)</td><td align="left" colspan="1" rowspan="1">64.0 (11.7)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (range)</td><td align="left" colspan="1" rowspan="1">64 (26.0&#8211;93.0)</td><td align="left" colspan="1" rowspan="1">49.5 (33.0&#8211;85.0)</td><td align="left" colspan="1" rowspan="1">64 (26.0&#8211;93.0)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Gender, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><bold>0.004</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td align="left" colspan="1" rowspan="1">90 (43.1)</td><td align="left" colspan="1" rowspan="1">10 (83.3)</td><td align="left" colspan="1" rowspan="1">80 (40.6)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Female</td><td align="left" colspan="1" rowspan="1">119 (56.9)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">117 (59.4)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Race, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.605</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Caucasian</td><td align="left" colspan="1" rowspan="1">184 (88.0)</td><td align="left" colspan="1" rowspan="1">10 (83.3)</td><td align="left" colspan="1" rowspan="1">174 (88.3)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Others</td><td align="left" colspan="1" rowspan="1">25 (12.0)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">23 (11.7)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cigarette smoking status, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.180</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Never</td><td align="left" colspan="1" rowspan="1">86 (41.1)</td><td align="left" colspan="1" rowspan="1">8 (66.7)</td><td align="left" colspan="1" rowspan="1">78 (39.6)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Former</td><td align="left" colspan="1" rowspan="1">63 (30.1)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">61 (31.0)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Current</td><td align="left" colspan="1" rowspan="1">60 (28.7)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">58 (29.4)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoking intensity among all smokers (n&#160;=&#160;119), n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.046</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Light (100 cigarettes-20 pack-years)</td><td align="left" colspan="1" rowspan="1">37 (30.1)</td><td align="left" colspan="1" rowspan="1">3 (75.0)</td><td align="left" colspan="1" rowspan="1">34 (28.6)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Heavy (&gt;20 pack-years)</td><td align="left" colspan="1" rowspan="1">86 (69.9)</td><td align="left" colspan="1" rowspan="1">1 (25.0)</td><td align="left" colspan="1" rowspan="1">85 (71.4)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoking Intensity (all patients), n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.017</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Never-light (0&#8211;20 pack-years)</td><td align="left" colspan="1" rowspan="1">123 (58.9)</td><td align="left" colspan="1" rowspan="1">11 (91.7)</td><td align="left" colspan="1" rowspan="1">112 (56.9)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Heavy (&gt;20 pack-years)</td><td align="left" colspan="1" rowspan="1">86 (41.1)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1">85 (43.1)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Tumor grade, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.679</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Well</td><td align="left" colspan="1" rowspan="1">12 (5.7)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">12 (6.1)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Moderate</td><td align="left" colspan="1" rowspan="1">66 (31.6)</td><td align="left" colspan="1" rowspan="1">4 (33.3)</td><td align="left" colspan="1" rowspan="1">62 (31.5)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Poor</td><td align="left" colspan="1" rowspan="1">131 (62.7)</td><td align="left" colspan="1" rowspan="1">8 (66.7)</td><td align="left" colspan="1" rowspan="1">123 (62.4)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">ALK</italic> rearrangement, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.477</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">8 (3.8)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">8 (4.1)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">201 (96.2)</td><td align="left" colspan="1" rowspan="1">12 (100.0)</td><td align="left" colspan="1" rowspan="1">189 (95.9)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">EGFR</italic> mutation, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.889</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">38 (18.2)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">36 (18.3)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">171 (81.8)</td><td align="left" colspan="1" rowspan="1">10 (83.3)</td><td align="left" colspan="1" rowspan="1">161 (81.7)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Treatment, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.131</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;drug or drug-radiation therapy</td><td align="left" colspan="1" rowspan="1">143 (68.4)</td><td align="left" colspan="1" rowspan="1">11 (91.7)</td><td align="left" colspan="1" rowspan="1">132 (67.0)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;surgery and drug with/without radiation</td><td align="left" colspan="1" rowspan="1">16 (7.7)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1">15 (7.6)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;surgery only or other therapy</td><td align="left" colspan="1" rowspan="1">50 (23.9)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">50 (25.4)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Targeted therapy, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic> drug &#8211; Yes</td><td align="left" colspan="1" rowspan="1">15 (7.2)</td><td align="left" colspan="1" rowspan="1">8 (66.7)</td><td align="left" colspan="1" rowspan="1">7 (3.6)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic> drug &#8211; No</td><td align="left" colspan="1" rowspan="1">194 (92.8)</td><td align="left" colspan="1" rowspan="1">4 (33.3)</td><td align="left" colspan="1" rowspan="1">190 (96.4)</td><td colspan="1" rowspan="1"/></tr></tbody></table></table-wrap></p><p id="p0080">None of the <italic toggle="yes">ROS1</italic> + patients had <italic toggle="yes">ALK</italic> mutations. Two <italic toggle="yes">ROS1</italic> + patients had co-occurring <italic toggle="yes">EGFR</italic> mutations (exon19): one was a woman who smoked and had stage IB disease, and another was a man who never-smoked and had stage IV disease. Further analysis of the EGFR + patients showed no preponderance either by sex, or by smoking status (<xref rid="appsec1" ref-type="sec">Supplementary Table 1</xref>).</p></sec><sec id="sec3.2"><label>3.2</label><title><italic toggle="yes">ROS1</italic> + rates by sex and smoking intensity</title><p id="p0085"><italic toggle="yes">ROS1</italic> + tumors were detected in 13 (6.4%) of 203 men and 11 (3.0%) of 368 women, <italic toggle="yes">P</italic>=0.052. As shown in <xref rid="appsec1" ref-type="sec">Supplementary Figure 1</xref>, 17 (5.1%) of 334 &#8220;never smokers&#8221; and 7 (2.9%) of 237 &#8220;smokers&#8221; were <italic toggle="yes">ROS1</italic> + (<italic toggle="yes">P</italic>=0.210). The &#8220;smoker&#8221; patients, categorized by smoking intensity, showed <italic toggle="yes">ROS1</italic> + rates at 5.7% in light-smokers and 1.8% in heavy-smokers (<italic toggle="yes">P</italic>=0.200). Stratifying <italic toggle="yes">ROS1</italic> + rate by sex and smoking intensity, we found <italic toggle="yes">ROS1</italic> + rates for never-, light- and heavy-smokers were 9.5%, 8.8%, 2.4% in men (<italic toggle="yes">P</italic>=0.113), and 3.6%, 2.8%, 1.2% in women (<italic toggle="yes">P</italic>=0.545), respectively. Never-smokers had significantly higher <italic toggle="yes">ROS1</italic> + rate in men (9.5%) than in women (3.6%, <xref rid="tbl3" ref-type="table">Table 3</xref>).<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>The distributions of <italic toggle="yes">ROS1</italic>+ by sex and smoking status and intensity.</p></caption><alt-text id="alttext0035">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Stage</th><th rowspan="2" colspan="1">Sex</th><th rowspan="2" colspan="1">Number (%) of patients</th><th colspan="9" rowspan="1">Smoking status and intensity<hr/></th></tr><tr><th colspan="1" rowspan="1">Never</th><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th><th colspan="1" rowspan="1">Light</th><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th><th colspan="1" rowspan="1">Heavy</th><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Total (%)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">ROS1</italic> + (%)</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Total (%)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">ROS1</italic> + (%)</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Total (%)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">ROS1</italic> + (%)</td><td colspan="1" rowspan="1"/></tr><tr><td rowspan="2" align="left" colspan="1">All stage</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">203 (35.6)</td><td align="left" colspan="1" rowspan="1">84 (25.1)</td><td align="left" colspan="1" rowspan="1">8 (9.5)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">34 (48.6)</td><td align="left" colspan="1" rowspan="1">3 (8.8)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">85 (50.9)</td><td align="left" colspan="1" rowspan="1">2 (2.4)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">368 (64.4)</td><td align="left" colspan="1" rowspan="1">250 (74.9)</td><td align="left" colspan="1" rowspan="1">9 (3.6)</td><td align="left" colspan="1" rowspan="1"><bold>0.044</bold></td><td align="left" colspan="1" rowspan="1">36 (51.4)</td><td align="left" colspan="1" rowspan="1">1 (2.8)</td><td align="left" colspan="1" rowspan="1">0.350</td><td align="left" colspan="1" rowspan="1">82 (49.1)</td><td align="left" colspan="1" rowspan="1">1 (1.2)</td><td align="left" colspan="1" rowspan="1">1.000</td></tr><tr><td rowspan="2" align="left" colspan="1">Stage IIIB-IV</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">90 (43.1)</td><td align="left" colspan="1" rowspan="1">29 (33.7)</td><td align="left" colspan="1" rowspan="1">6 (20.7)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">20 (50.1)</td><td align="left" colspan="1" rowspan="1">3 (15.0)</td><td rowspan="2" align="left" colspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">41 (47.7)</td><td align="left" colspan="1" rowspan="1">1 (2.4)</td><td rowspan="2" align="left" colspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">119 (56.9)</td><td align="left" colspan="1" rowspan="1">57 (66.3)</td><td align="left" colspan="1" rowspan="1">2 (3.5)</td><td align="left" colspan="1" rowspan="1">0.016</td><td align="left" colspan="1" rowspan="1">17 (45.9)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">45 (52.3)</td><td align="left" colspan="1" rowspan="1">0</td></tr></tbody></table></table-wrap></p><p id="p0090">When focusing on stage IIIB-IV patients, as shown in <xref rid="tbl2" ref-type="table">Table 2</xref>, the frequency of <italic toggle="yes">ROS1</italic> + in men (11.1%) was much higher than in women (1.7%); in never-smokers, men had higher <italic toggle="yes">ROS1</italic> + rate than women (20.7% vs. 3.5%, <xref rid="tbl3" ref-type="table">Table 3</xref>). <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100014337</institution-id><institution>Furthermore</institution></institution-wrap></funding-source>, the <italic toggle="yes">ROS1</italic> + rate in light-smokers (8.1%) was much higher than in heavy-smokers (1.2%); more specifically, we found 9.3%, 8.1% and 1.2% were <italic toggle="yes">ROS1</italic>+, respectively in never-, light-, and heavy smokers, supporting a similar <italic toggle="yes">ROS1</italic>+ rates between never- and light-smokers; the <italic toggle="yes">ROS1</italic> + rate in never- or light-smokers (8.9%) was significantly higher than that in heavy-smokers (1.2%).</p></sec><sec id="sec3.3"><label>3.3</label><title><italic toggle="yes">ROS1</italic>+ rates comparison with published studies</title><p id="p0095">Two hundred and two articles were identified and reviewed; eight studies were included for comparison of <italic toggle="yes">ROS1</italic> + (<xref rid="appsec1" ref-type="sec">Supplementary Figure 2</xref>). Of the eight studies, one had all Whites, one 79.4% Whites, one 88% non-Asian, one 89.8% Whites, and four were from European countries without information on racial distribution. All eight studies were included for the sex comparison, and seven of eight studies with available smoking history were for smoking status comparison. Comparing to the 8 published studies with <italic toggle="yes">ROS1</italic> + by sex, in which 6 included all-stage patients and two advanced-stage, the frequencies of <italic toggle="yes">ROS1</italic> + were 0.3%&#8211;1.8% in men and 0.7%&#8211;10.2% in women; women were found comparable or higher than men in <italic toggle="yes">ROS1</italic> + rates (<italic toggle="yes">Ps</italic>=0.5809&#8211;0.0001). As shown in <xref rid="appsec1" ref-type="sec">Supplementary Table 2</xref>, the <italic toggle="yes">ROS1</italic> + rate of women in our study was similar to what were reported; however, men had much higher <italic toggle="yes">ROS1</italic> + rate in our study than that previously reported (<italic toggle="yes">P</italic>&#160;&lt;&#160;0.002).</p><p id="p0100">Additionally, our results were compared to the seven studies that ascertained <italic toggle="yes">ROS1</italic> + rates by smoking history (<xref rid="appsec1" ref-type="sec">Supplementary Table 3</xref>), where we found five studies involved all-stage patients and two focused on advanced stage [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib30" ref-type="bibr">[30]</xref>, <xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>]. The <italic toggle="yes">ROS1</italic> + rates were 2.4%&#8211;6.1% in never-smokers and 0.3%&#8211;1.8% in smokers for all-stage patients [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib30" ref-type="bibr">[30]</xref>, <xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>], and 3.4%&#8211;12.5% in never-smokers and 0.5%&#8211;1.9% in all smokers for advanced-stage patients [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib10" ref-type="bibr">10</xref>]. One study [<xref rid="bib2" ref-type="bibr">2</xref>] subgrouped ever smokers as &#8220;light smoker (n&#160;=&#160;62)&#8221; and &#8220;smoker (n&#160;=&#160;695)&#8221; with the <italic toggle="yes">ROS1</italic> + rates respectively at 1.6% and 0.3% (<italic toggle="yes">P</italic>=0.112), but without the definition of &#8220;light smoker&#8221;; authors reported similar <italic toggle="yes">ROS1</italic> + rates at 5.9% in never-smokers and 1.6% in light-smokers (<italic toggle="yes">P</italic>=0.171), both higher than the 0.3% in smokers (<italic toggle="yes">P</italic>&#160;&lt;&#160;0.001). One study [<xref rid="bib8" ref-type="bibr">8</xref>] defined never-, light-, heavy-smokers as &lt;1py, 1-15py, &gt;15py, demonstrating <italic toggle="yes">ROS1</italic> + tumors in 22/600 (3.7%) never-smokers and 4/465 (0.9%) light-smokers, both of which were higher than 1/1330 (0.07%) in heavy-smokers (<italic toggle="yes">P</italic>=0.0001, 0.0057). The frequency of <italic toggle="yes">ROS1</italic> + in never- and heavy-smokers in our study were comparable to the reported rates [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib30" ref-type="bibr">[30]</xref>, <xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>]; the light-smokers in our study was similar to the never-smokers, i.e., much higher than ever smokers reported in literature (<xref rid="appsec1" ref-type="sec">Supplementary Table 3</xref>).</p></sec><sec id="sec3.4"><label>3.4</label><title>Treatment response</title><p id="p0105">A total of 9 <italic toggle="yes">ROS1</italic> + patients with 67% in stage IIIB-IV received <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted drugs, including crizotinib, ceritinib, entrectinib and lorlatinib; 4 late-stage <italic toggle="yes">ROS1</italic> + patients did not receive <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted therapy since they were diagnosed and treated prior to the development of such therapy. Five of the 9 patients received crizotinib as first-line monotherapy; one as postoperative adjuvant therapy and another with unknown response were excluded from the analysis (<xref rid="appsec1" ref-type="sec">Supplementary Figure 3</xref>). The ORR was 43% and the DCR was 86%, and for first line therapy, these rates were 60% and 100%, respectively. However, the ORR and DCR decreased with second- or third-line therapy (25% and 25%, respectively). Two patients had early progression on first-line crizotinib (&lt;3 months) followed by pemetrexed and ceritinib as second- and third-line therapy.</p><p id="p0110">Change in tumor burden, the best indicator of response, was described for each of the 7 evaluable stage IIIB-IV patients as shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>; three patients had stable disease, and three had partial responses, with reductions in tumor burden that ranged from 55.6% to 71.4%. Median DFS among these 7 patients was 7.9 months, and the DFS at 12 months was 42.9%.<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Percent change in tumor burden among patients who received <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic> targeted drugs (n&#160;=&#160;7). The panel showed the best response of each patient with <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic> targeted drugs. The bar indicated the best percentage of tumor shrinkage from baseline size. One patient had progressive disease with a 49.7% tumor increase, indicating the drug was not effective in this patient (purple). Three patients were evaluated as stable disease; one of them had a tumor increased at 5.2%; one had no change of tumor size and the other one had a tumor decrease at 28.9% (red). Three patients notably benefited from the treatment and showed partial response to the drugs with tumor shrinkages at 55.6%, 64.2%, 71.4%, respectively (green). Response definitions according to RECIST guidelines<sup>1</sup>; broken line reflects the 30% minimum decrease required for a partial response. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0115">Moreover, the newer generation of <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic> targeted drugs were observed during the long-term, routine patient follow-up. Follow-up treatment of four patients (<xref rid="appsec1" ref-type="sec">Supplementary Table 4</xref>), whose disease progressed after crizotinib (drug 1) when newer <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted therapy (drug 2&#8211;4) became available, showed remarkable benefit in prolonged survival time. All four patients were no more than 65 years old, never- or light-smokers, and diagnosed stage IV disease. Cases 1 and 2, who were treated by entrectinib, survived more than five years; both had intracranial metastases and were treated with radiotherapy before the use of entrectinib. Cases 3 and 4 were on lorlatinib and survived more than six and seven years, with response duration of 63 months and 12 months, respectively.</p></sec><sec id="sec3.5"><label>3.5</label><title>Recurrence/progression</title><p id="p0120">For patients with lung cancer recurrence, progression, or both that occurred after initial treatment and during follow-up, there was no significant difference in clinical characteristics between <italic toggle="yes">ROS1</italic> + and <italic toggle="yes">ROS1</italic>- groups.</p><p id="p0125">Among the 24 <italic toggle="yes">ROS1</italic> + patients, significant differences were observed based on presence of metastases; the 12 patients with metastases were predominantly men (83% vs. 25%; <italic toggle="yes">P</italic>=0.004), younger (mean age 53 vs. 64 years; <italic toggle="yes">P</italic>=0.046) and had more aggressive tumors (100% vs. 58%; <italic toggle="yes">P</italic>=0.039) compared to non-metastatic patients. Metastatic regions included within the lung (n&#160;=&#160;4), parietal pleura (n&#160;=&#160;3), and distant metastases (n&#160;=&#160;5) of brain, vertebra, ribs, and liver.</p></sec><sec id="sec3.6"><label>3.6</label><title>Survival</title><p id="p0130">While being a smoker was consistently associated with poorer OS (HR, 1.62; 95% CI, 1.25 to 2.0; <italic toggle="yes">P</italic>&#160;&lt;&#160;0.001) and DFS (HR, 2.70; 95%CI, 1.86&#8211;3.94; <italic toggle="yes">P</italic>&#160;&lt;&#160;0.001), late-stage disease was a significant risk factor only for OS (HR, 5.38; 95% CI, 3.83 to 7.55; <italic toggle="yes">P</italic>&#160;&lt;&#160;0.001). After adjusting for smoking and tumor stage, OS had no difference between <italic toggle="yes">ROS1</italic> + and <italic toggle="yes">ROS1</italic>- (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A), and median survival was 6.3 and 5.1 years, respectively. Like OS, <italic toggle="yes">ROS1</italic> status was not associated with DFS after adjusting for smoking and tumor stage (<italic toggle="yes">P</italic>=0.921, <xref rid="fig2" ref-type="fig">Fig. 2</xref>B). The covariates without statistical significance were not adjusted in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>CoxPH curves in <italic toggle="yes">ROS1</italic>+ and <italic toggle="yes">ROS1</italic>- patients. (A) Overall survival in all patients adjusted for smoking and stage truncated at 10 years. (B) Disease-free survival in all patients adjusted for smoking and stage truncated at 10 years. (C) Overall survival among patients with stage IIIB-IV adjusted for smoking and treatment truncated at 5 years. (D) Disease-free survival among patients with stage IIIB-IV adjusted for smoking, treatment and sex truncated at 5 years.</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0135">In patients with stage IIIB-IV, <italic toggle="yes">ROS1</italic> + patients had better OS than <italic toggle="yes">ROS1-</italic> patients in the univariate analysis (median, 4.5 vs. 1.3 years, <italic toggle="yes">P</italic>=0.029). In the multivariate model, <italic toggle="yes">ROS1</italic> status remained significant when adjusted for age, smoking status, and treatment (<xref rid="tbl4" ref-type="table">Table 4</xref> and <xref rid="fig2" ref-type="fig">Fig. 2</xref>C). However, when adjusted for smoking history and <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted drug, <italic toggle="yes">ROS1</italic> status was not significant (<xref rid="tbl4" ref-type="table">Table 4</xref>). For DFS, there was no significant difference between <italic toggle="yes">ROS1</italic> + and <italic toggle="yes">ROS1-</italic> in patients with late-stage tumors (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D) when adjusting for smoking, treatment and sex truncated at 5 years.<table-wrap position="float" id="tbl4" orientation="portrait"><label>Table 4</label><caption><p>Overall survival of patients with stage IIIB-IV lung cancer (n&#160;=&#160;209).</p></caption><alt-text id="alttext0040">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Variable</th><th colspan="1" rowspan="1">Hazard ratio (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">P-value</italic></th></tr></thead><tbody><tr><td colspan="3" align="left" rowspan="1">Cox model 1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">ROS1</italic> status</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><bold>0.026</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">0.51 (0.29&#8211;0.91)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="3" align="left" rowspan="1">&#160;Treatment</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Drug or drug-related therapy</td><td align="left" colspan="1" rowspan="1">0.48 (0.33&#8211;0.70)</td><td align="left" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Surgery and drug with/without radiation</td><td align="left" colspan="1" rowspan="1">0.25 (0.12&#8211;0.52)</td><td align="left" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Surgery only or other therapy</td><td align="left" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="3" align="left" rowspan="1">&#160;Age</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;55</td><td align="left" colspan="1" rowspan="1">0.81 (0.53&#8211;1.24)</td><td align="left" colspan="1" rowspan="1">0.321</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;56-76</td><td align="left" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;77</td><td align="left" colspan="1" rowspan="1">0.74 (0.44&#8211;1.25)</td><td align="left" colspan="1" rowspan="1">0.256</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Smoking status</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.008</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Ever smoker</td><td align="left" colspan="1" rowspan="1">1.60 (1.13&#8211;2.28)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Never-smoker</td><td align="left" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Cox model 2</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">ROS1</italic> status</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><bold>0.265</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">0.57 (0.20&#8211;1.62)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic> drug</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.311</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">0.60 (0.22&#8211;1.69)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Smoking status</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.044</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Ever smokers</td><td align="left" colspan="1" rowspan="1">1.432 (1.0&#8211;2.04)</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Never-smokers</td><td align="left" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/></tr></tbody></table></table-wrap></p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0140">Our study observed a higher frequency of <italic toggle="yes">ROS1</italic> + tumor in men than in women, particularly in stage IIIB-IV patients, which has not been consistently or adequately reported; specifically, through a literature review and comparison, we found female preponderance [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib30" ref-type="bibr">30</xref>,<xref rid="bib32" ref-type="bibr">32</xref>] or no sex disparity [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib31" ref-type="bibr">31</xref>]. Two studies having patient population and gender proportion comparable to our study demonstrated a similar <italic toggle="yes">ROS1</italic> + rate in men and women among 3115 all-stage patients (1.1% vs. 0.9%; <italic toggle="yes">P</italic>=0.581) [<xref rid="bib8" ref-type="bibr">8</xref>] and a male preponderance in 550 advanced-stage patients (1.8% vs. 0.7; <italic toggle="yes">P</italic>=0.246) [<xref rid="bib6" ref-type="bibr">6</xref>], respectively. These two studies included large sample sizes from multi-center registries but did not focus analysis on patients with <italic toggle="yes">ROS1</italic> alterations. In contrast, our study was designed to have complete sampling of never- and light-smokers, who were known to harbor higher rate of <italic toggle="yes">ROS1</italic> + tumors yet severely underrepresented in non-selected or randomly or conveniently sampled NSCLC patients of European ancestry.</p><p id="p0145">Few studies analyzed the distributions of <italic toggle="yes">ROS1</italic> + tumors in men and women varied by smoking history as our study has done. We found men had higher <italic toggle="yes">ROS1</italic> + rates in never-, light-, and heavy-smokers than women; this sex difference in never-smokers reached statistical significance (<italic toggle="yes">P</italic>=0.044) for all-stage patients and was more pronounced for stage III-IV patients (<italic toggle="yes">P</italic>=0.016).</p><p id="p0150">It is known that a prominently higher incidence of <italic toggle="yes">ROS1</italic> + tumors occurred in never-smokers [<xref rid="bib2" ref-type="bibr">2</xref>], but we found studies reporting the relationship of <italic toggle="yes">ROS1</italic> + and smoking intensity were insufficient. Light-smokers were categorized separately from other smokers and shown to have a higher frequency of <italic toggle="yes">ROS1</italic> + at 1.6% [<xref rid="bib2" ref-type="bibr">2</xref>]; however, the definition of smoking intensity was not provided and patients with unknown smoking history had a higher <italic toggle="yes">ROS1</italic> + rate than light-smokers (7.2% vs. 5.8%) in that study. The GENIE project defined light-smokers as 15py or less, and reported light-smokers had a higher <italic toggle="yes">ROS1</italic> + rate than heavy-smokers but much lower than never-smokers [<xref rid="bib8" ref-type="bibr">8</xref>]<italic toggle="yes">.</italic> Although the widely used definition of a never-smoker was a person who consumed fewer than 100 cigarettes lifetime, per the U.S. Centers for Disease Control and Prevention [<xref rid="bib33" ref-type="bibr">33</xref>], there was no consensus on the cut-off point for light- and heavy-smokers in the published literature; most studies used 10py [<xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref>, <xref rid="bib36" ref-type="bibr">[36]</xref>], 20py [<xref rid="bib37" ref-type="bibr">[37]</xref>, <xref rid="bib38" ref-type="bibr">[38]</xref>, <xref rid="bib39" ref-type="bibr">[39]</xref>, <xref rid="bib40" ref-type="bibr">[40]</xref>, <xref rid="bib41" ref-type="bibr">[41]</xref>, <xref rid="bib42" ref-type="bibr">[42]</xref>], or 30py [<xref rid="bib43" ref-type="bibr">[43]</xref>, <xref rid="bib44" ref-type="bibr">[44]</xref>, <xref rid="bib45" ref-type="bibr">[45]</xref>] of cigarettes, and others defined light-smokers at 15py [<xref rid="bib46" ref-type="bibr">46</xref>,<xref rid="bib47" ref-type="bibr">47</xref>], 21.5py [<xref rid="bib48" ref-type="bibr">48</xref>], 33py [<xref rid="bib49" ref-type="bibr">49</xref>], 40py [<xref rid="bib50" ref-type="bibr">50</xref>] and 60py [<xref rid="bib51" ref-type="bibr">51</xref>]. Only a few studies had definite start point of cigarette consumption for light-smokers (1-15py, 0&lt; py&#160;&lt;&#160;10) [<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib52" ref-type="bibr">52</xref>]. Noted, 1-py of a light smoker equals 7300 cigarettes, much greater than a never smoker.</p><p id="p0155">We investigated the frequency of <italic toggle="yes">ROS1</italic>+ among patients with complete smoking history and intensity information, using a definition of 100 cigarettes-20py for light-smokers. Our results indicated that light-smokers had much higher incidence of <italic toggle="yes">ROS1</italic> + than ever smokers reported in comparable studies. Six published studies included for comparison defined never-smokers as &#8220;no history of smoking&#8221; without specific counts of cigarettes, among which the highest incidence of <italic toggle="yes">ROS1</italic> + rate was in a French population for all-stage patients [<xref rid="bib31" ref-type="bibr">31</xref>] and in a Italy population for advanced-stage patients [<xref rid="bib10" ref-type="bibr">10</xref>]. In the French study, all patients were Caucasians; among them, 14 (2.5%) were <italic toggle="yes">ROS1</italic> + with 6 never-smokers (6.1% <italic toggle="yes">ROS1</italic>+), 4 light-smokers (5-20py) and 4 heavy-smokers (25-80py); unfortunately, the denominator of light- and heavy-smokers were not provided. In the Italy study, 12.5% &#8220;nonsmokers&#8221; and 1.9% &#8220;smokers&#8221; harbored <italic toggle="yes">ROS1</italic> + tumors, supporting our findings of the <italic toggle="yes">ROS1</italic> + rates in never-light smokers versus heavy-smokers among stage IIIB-<funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000026</institution-id><institution>IV</institution></institution-wrap></funding-source> patients. Although the mechanism why <italic toggle="yes">ROS1</italic> + being more prevalent in light-smokers is unknown, knowing the high-risk subpopulation could assist future studies designed to efficiently accrue <italic toggle="yes">ROS1</italic> + patients. We excluded studies specifically in Asian population in our literature comparison; this was because their race of the participants was not comparable to our study; therefore, our results predominantly supported the frequency of <italic toggle="yes">ROS1</italic> + in Caucasian populations.</p><p id="p0160">To date, molecular analyses for detecting druggable genes, e.g.<italic toggle="yes">, EGFR</italic>, <italic toggle="yes">ALK</italic>, <italic toggle="yes">ROS1</italic>, <italic toggle="yes">Kirsten rat sarcoma virus (KRAS)</italic>, <italic toggle="yes">V-raf murine sarcoma oncogene homolog B1</italic> (<italic toggle="yes">BRAF</italic>), <italic toggle="yes">MET</italic> and <italic toggle="yes">human epidermal growth factor receptor</italic> (<italic toggle="yes">HER2</italic>), have become part of standard care in advanced-stage non-squamous NSCLC [<xref rid="bib53" ref-type="bibr">[53]</xref>, <xref rid="bib54" ref-type="bibr">[54]</xref>, <xref rid="bib55" ref-type="bibr">[55]</xref>]. <italic toggle="yes">ROS1</italic> + appeared to be mutually exclusive of <italic toggle="yes">ALK</italic>, and two <italic toggle="yes">EGFR</italic> mutations were observed in the <italic toggle="yes">ROS1</italic> + patients in our study. While this could be due to chance, previous studies have suggested that <italic toggle="yes">ROS1</italic> + presents in a greater proportion of lung tumors that lack other genetic changes. Among 25 <italic toggle="yes">ROS1</italic> + cases [<xref rid="bib56" ref-type="bibr">56</xref>], 17 were mutually exclusive of other mutations, while six had <italic toggle="yes">EGFR</italic> and two had <italic toggle="yes">KRAS</italic> mutations. Concomitant <italic toggle="yes">ROS1</italic> and <italic toggle="yes">ALK</italic> rearrangement was extremely rare but found in <italic toggle="yes">EGFR</italic> wild-type patients [<xref rid="bib57" ref-type="bibr">57</xref>]. As far as could be ascertained in the literature, only several case reports mentioned that patients with oncogene-associated NSCLC, including <italic toggle="yes">ROS1</italic>, may present a particular pattern of metastasis and associated with unusual site of metastases [<xref rid="bib58" ref-type="bibr">58</xref>,<xref rid="bib59" ref-type="bibr">59</xref>]; no unusual site of metastases was observed in the <italic toggle="yes">ROS1</italic> + patients in our study.</p><p id="p0165">As recommended by National Comprehensive Cancer Network (NCCN) guideline [<xref rid="bib60" ref-type="bibr">60</xref>], the first-line standard care for <italic toggle="yes">ROS1</italic>+ advanced-stage NSCLC should be the <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted drugs. In stage IIIB-IV patients with <italic toggle="yes">ROS1</italic> + had better OS than <italic toggle="yes">ROS1-</italic> after adjusting for age, sex, smoking status, and treatment because most of them were treated by <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted drugs. Since the crizotinib was approved as the first-line therapy for <italic toggle="yes">ROS1</italic>+ NSCLC patients, increasing <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted drugs were developed to against resistance with better brain penetration. While the ORR of 43% was substantially lower than what has been reported in a clinical trial of crizotinib (72%) [<xref rid="bib13" ref-type="bibr">13</xref>], the DCR of 86% was only slightly lower than the 100% reported in that trial. These lower rates may not be surprising given the real-world clinical cohort of our study. Nevertheless, one patient in our study has benefited more than 65 months from the first-line crizotinib, which was longer than the 51.4 months median OS from the updated results of PROFILE 1001 study [<xref rid="bib61" ref-type="bibr">61</xref>], validating crizotinib was effective in patients with <italic toggle="yes">ROS1</italic>+, although resistance to crizotinib may still occur.</p><p id="p0170">Furthermore, newer molecular targeted drugs, such as entrectinib and lorlatinib, showed striking OS benefits in our study, ranging between 87 and 61 months, relative to the OS using only crizotinib (7&#8211;65 months). Entrectinib was designed to penetrate the blood-brain barrier and found to prolong survival in <italic toggle="yes">ROS1</italic> + NSCLC patients with brain metastasis; the overall response of patients with baseline central nervous system disease was 55% [<xref rid="bib14" ref-type="bibr">14</xref>]. A recent study of 67 stage-IV non-squamous NSCLC patients with <italic toggle="yes">ROS1</italic> + showed disappointing OS (5.2 months) and PFS (4.3 months) due to brain metastasis after receiving <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted drug [<xref rid="bib12" ref-type="bibr">12</xref>]. To date in phase I-II trials, patients using lorlatinib experienced 21.1 months overall median duration of response in advanced-stage <italic toggle="yes">ROS1</italic> + NSCLC patients; whereas for the patients only treated by crizotinib previously, the reported median duration of response was 13.9 months, with a 35% ORR [<xref rid="bib15" ref-type="bibr">15</xref>]. In our extended follow-up of surviving patients with <italic toggle="yes">ROS1</italic> + tumors, those treated by lorlatinib showed significant advantage in response duration (12&#8211;63 months) compared to the reported results. Thus, the follow-up treatment with the newer generation of <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted drugs after failure to crizotinib tended to be more effective, which need to be validated by prospective study with larger sample size.</p><sec id="sec4.1"><label>4.1</label><title>Study limitations</title><p id="p0175">Limitations include the retrospective nature of the study, as well as potential bias from misclassification resulting from the use of self-report information and arbitrary definition of smoking status and intensity. Additionally, even though we have carefully adjusted potential confounding factors, because of the relatively small <italic toggle="yes">ROS1</italic> + sample size for heavy smokers given the lowest <italic toggle="yes">ROS1</italic> + rate in this group, prudence should be used when interpreting the results and implications of this study.</p></sec></sec><sec id="sec5"><label>5</label><title>Conclusion</title><p id="p0180">This study found men had higher frequency of <italic toggle="yes">ROS1</italic> + than women and confirmed <italic toggle="yes">ROS1</italic> + had a similar frequency among never- and light-smokers, and a lower frequency in heavy-smokers, especially among stage IIIB-IV patients. Use of newer-generation <italic toggle="yes">ALK</italic>/<italic toggle="yes">ROS1</italic>-targeted drugs entrectinib and lorlatinib demonstrated prolonged efficacy in <italic toggle="yes">ROS1</italic> + patients resistant to crizotinib. These results call for investigations to confirm and mechanistically explain the prevalence of <italic toggle="yes">ROS1</italic> + tumors in men and light-smokers, and once validated, would assist future studies and trials designed to efficiently accrue <italic toggle="yes">ROS1</italic> + patients.</p></sec><sec id="sec6"><title>Ethics statement</title><p id="p0185">The authors declared that informed consent was granted by Mayo Foundation IRB (# 225-99) and signed by all enrolled patients. This study critically complied with all regulations of IRB.</p></sec><sec sec-type="data-availability" id="sec7"><title>Data availability statement</title><p id="p0190">The patients&#8217; original data are confidential. The deidentified or aggregated data will be made available on request.</p></sec><sec id="sec8"><title>CRediT authorship contribution statement</title><p id="p0195"><bold>Yanmei Peng:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Investigation, Funding acquisition, Formal analysis, Conceptualization. <bold>Vinicius Ernani:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Methodology, Investigation. <bold>Dan Liu:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Methodology, Formal analysis, Data curation. <bold>Qian Guo:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Methodology, Formal analysis, Data curation. <bold>Markay Hopps:</bold> Writing &#8211; review &amp; editing, Funding acquisition. <bold>Joseph C. Cappelleri:</bold> Writing &#8211; review &amp; editing, Funding acquisition. <bold>Ruchi Gupta:</bold> Software, Methodology, Formal analysis. <bold>Mariza de Andrade:</bold> Software, Methodology, Formal analysis. <bold>Jun Chen:</bold> Visualization, Validation, Investigation. <bold>Eunhee S. Yi:</bold> Software, Methodology, Formal analysis. <bold>Ping Yang:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Supervision, Resources, Project administration, Funding acquisition, Conceptualization.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0200">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Wagle</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics</article-title><source>CA A Cancer J. Clin.</source><volume>73</volume><issue>1</issue><year>2023</year><fpage>17</fpage><lpage>48</lpage><comment>2023</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21763</pub-id><pub-id pub-id-type="pmid">36633525</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Bergethon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lovly</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Massion</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Siwak-Tapp</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mark</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Batten</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wilner</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Engelman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Mino-Kenudson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Iafrate</surname><given-names>A.J.</given-names></name></person-group><article-title>ROS1 rearrangements define a unique molecular class of lung cancers</article-title><source>J. Clin. Oncol.</source><volume>30</volume><issue>8</issue><year>2012</year><fpage>863</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">22215748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2011.35.6345</pub-id><pub-id pub-id-type="pmcid">PMC3295572</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Le</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Theodoro</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Skokan</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Aisner</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Berge</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Terracciano</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Cappuzzo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Incarbone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roncalli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alloisio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Santoro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Varella-Garcia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doebele</surname><given-names>R.C.</given-names></name></person-group><article-title>Identifying and targeting ROS1 gene fusions in non-small cell lung cancer</article-title><source>Clin. Cancer Res.</source><volume>18</volume><issue>17</issue><year>2012</year><fpage>4570</fpage><lpage>4579</lpage><pub-id pub-id-type="pmid">22919003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-12-0550</pub-id><pub-id pub-id-type="pmcid">PMC3703205</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Soda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Togashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sakata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hatano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Asaka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hamanaka</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ninomiya</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uehara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lim Choi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>Y.</given-names></name></person-group><article-title>RET, ROS1 and ALK fusions in lung cancer</article-title><source>Nat. Med.</source><volume>18</volume><issue>3</issue><year>2012</year><fpage>378</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">22327623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.2658</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>T.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name></person-group><article-title>ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features</article-title><source>Lung Cancer</source><volume>84</volume><issue>2</issue><year>2014</year><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">24629636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2014.02.007</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Mazieres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Drilon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lusque</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mhanna</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cortot</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Mezquita</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thai</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Mascaux</surname><given-names>C.</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Veillon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Van den Heuvel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peled</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fr&#252;h</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Gounant</surname><given-names>V.</given-names></name><name name-style="western"><surname>Popat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Diebold</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sabari</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>V.W.</given-names></name><name name-style="western"><surname>Rothschild</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Bironzo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Martinez-Marti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Curioni-Fontecedro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rosell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lattuca-Truc</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wiesweg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Besse</surname><given-names>B.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Barlesi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schouten</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Wakelee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Zalcman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Novello</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Milia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gautschi</surname><given-names>O.</given-names></name></person-group><article-title>Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry</article-title><source>Ann. Oncol.</source><volume>30</volume><issue>8</issue><year>2019</year><fpage>1321</fpage><lpage>1328</lpage><pub-id pub-id-type="pmid">31125062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdz167</pub-id><pub-id pub-id-type="pmcid">PMC7389252</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Provencio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cobo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodriguez-Abreu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Carcereny</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cantero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bernab&#233;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benitez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Massut&#237;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Del Barco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garc&#237;a Campelo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guirado</surname><given-names>M.</given-names></name><name name-style="western"><surname>Camps</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Gonz&#225;lez Larriba</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sala</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Juan-Vidal</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bosch-Barrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oramas</surname><given-names>J.</given-names></name><name name-style="western"><surname>D&#243;mine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trigo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Calzas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Morilla</surname><given-names>I.</given-names></name><name name-style="western"><surname>Padilla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pimentao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Torrente</surname><given-names>M.</given-names></name></person-group><article-title>Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics</article-title><source>BMC Cancer</source><volume>22</volume><issue>1</issue><year>2022</year><fpage>732</fpage><pub-id pub-id-type="pmid">35790916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-022-09830-8</pub-id><pub-id pub-id-type="pmcid">PMC9254518</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Adib</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nassar</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Abou Alaiwi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Groha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akl</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Sholl</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Awad</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>J&#1235;nne</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Gusev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kwiatkowski</surname><given-names>D.J.</given-names></name></person-group><article-title>Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology</article-title><source>Genome Med.</source><volume>14</volume><issue>1</issue><year>2022</year><fpage>39</fpage><pub-id pub-id-type="pmid">35428358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-022-01041-x</pub-id><pub-id pub-id-type="pmcid">PMC9013075</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Warth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Muley</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dienemann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Goeppert</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stenzinger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schnabel</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Schirmacher</surname><given-names>P.</given-names></name><name name-style="western"><surname>Penzel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Weichert</surname><given-names>W.</given-names></name></person-group><article-title>ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases</article-title><source>Histopathology</source><volume>65</volume><issue>2</issue><year>2014</year><fpage>187</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">24456475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/his.12379</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Marchetti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barberis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Lorito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pace</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Di Lisio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Felicioni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guerini-Rocco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vingiani</surname><given-names>A.</given-names></name><name name-style="western"><surname>D'Antuono</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liberatore</surname><given-names>M.</given-names></name><name name-style="western"><surname>Filice</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Marinis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Passaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Irtelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Crin&#242;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mucilli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Buttitta</surname><given-names>F.</given-names></name></person-group><article-title>ROS1 gene fusion in advanced lung cancer in women: a ssystematic analysis, review of the literature, and diagnostic algorithm</article-title><source>JCO Precis Oncol</source><volume>1</volume><year>2017</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.16.00010</pub-id><pub-id pub-id-type="pmid">35172481</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.G.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Du</surname><given-names>K.Q.</given-names></name></person-group><article-title>Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1-positive non-small cell lung cancer</article-title><source>Oncol. Lett.</source><volume>17</volume><issue>3</issue><year>2019</year><fpage>3466</fpage><lpage>3474</lpage><pub-id pub-id-type="pmid">30867785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2019.9949</pub-id><pub-id pub-id-type="pmcid">PMC6396181</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Ten Berge</surname><given-names>D.M.H.J.</given-names></name><name name-style="western"><surname>Damhuis</surname><given-names>R.A.M.</given-names></name><name name-style="western"><surname>Aerts Recourses</surname><given-names>J.G.J.V.</given-names></name><name name-style="western"><surname>Dingemans</surname><given-names>A.-M.C.</given-names></name></person-group><article-title>Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in The Netherlands</article-title><source>Lung Cancer</source><volume>181</volume><year>2023</year><fpage>107253</fpage><pub-id pub-id-type="pmid">37236088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2023.107253</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Bang</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Salgia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Riely</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Varella-Garcia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Doebele</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Le</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shreeve</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Tye</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Wilner</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Iafrate</surname><given-names>A.J.</given-names></name></person-group><article-title>Crizotinib in ROS1-rearranged non-small-cell lung cancer</article-title><source>N. Engl. J. Med.</source><volume>371</volume><issue>21</issue><year>2014</year><fpage>1963</fpage><lpage>1971</lpage><pub-id pub-id-type="pmid">25264305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1406766</pub-id><pub-id pub-id-type="pmcid">PMC4264527</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Drilon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Siena</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dziadziuszko</surname><given-names>R.</given-names></name><name name-style="western"><surname>Barlesi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Krebs</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>de Braud</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rolfo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Seto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>John</surname><given-names>T.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karapetis</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Arkenau</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Ohe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Chae</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Otterson</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D.S.W.</given-names></name><name name-style="western"><surname>Prenen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Riehl</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chow-Maneval</surname><given-names>E.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>N.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Doebele</surname><given-names>R.C.</given-names></name></person-group><article-title>Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials</article-title><source>Lancet Oncol.</source><volume>21</volume><issue>2</issue><year>2020</year><fpage>261</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">31838015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(19)30690-4</pub-id><pub-id pub-id-type="pmcid">PMC7811790</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Chiari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Riely</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Besse</surname><given-names>B.</given-names></name><name name-style="western"><surname>Soo</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Thurm</surname><given-names>H.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Peltz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Abbattista</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S.I.</given-names></name></person-group><article-title>Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial</article-title><source>Lancet Oncol.</source><volume>20</volume><issue>12</issue><year>2019</year><fpage>1691</fpage><lpage>1701</lpage><pub-id pub-id-type="pmid">31669155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(19)30655-2</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Gendarme</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bylicki</surname><given-names>O.</given-names></name><name name-style="western"><surname>Chouaid</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guisier</surname><given-names>F.</given-names></name></person-group><article-title>ROS-1 fusions in non-small-cell lung cancer: evidence to date</article-title><source>Curr. Oncol.</source><volume>29</volume><issue>2</issue><year>2022</year><fpage>641</fpage><lpage>658</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/curroncol29020057</pub-id><pub-id pub-id-type="pmcid">PMC8870726</pub-id><pub-id pub-id-type="pmid">35200557</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Isla</surname><given-names>D.</given-names></name><name name-style="western"><surname>Majem</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vi&#241;olas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Artal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blasco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garrido</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rem&#243;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baquedano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borr&#225;s</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Die Trill</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Campelo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Juan</surname><given-names>O.</given-names></name><name name-style="western"><surname>Le&#243;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lianes</surname><given-names>P.</given-names></name><name name-style="western"><surname>L&#243;pez-R&#237;os</surname><given-names>F.</given-names></name><name name-style="western"><surname>Molins</surname><given-names>L.</given-names></name><name name-style="western"><surname>Planchuelo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cobo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paz-Ares</surname><given-names>L.</given-names></name><name name-style="western"><surname>Trigo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>de Castro</surname><given-names>J.</given-names></name></person-group><article-title>A consensus statement on the gender perspective in lung cancer</article-title><source>Clin. Transl. Oncol.</source><volume>19</volume><issue>5</issue><year>2017</year><fpage>527</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">27885542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12094-016-1578-x</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Aubry</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Wampfler</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Edell</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Thibodeau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adjei</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Jett</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deschamps</surname><given-names>C.</given-names></name></person-group><article-title>Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003</article-title><source>Chest</source><volume>128</volume><issue>1</issue><year>2005</year><fpage>452</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">16002972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.128.1.452</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Aubry</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Deschamps</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Okuno</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Sugimura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pankratz</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P.</given-names></name></person-group><article-title>Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases</article-title><source>J. Thorac. Cardiovasc. Surg.</source><volume>131</volume><issue>5</issue><year>2006</year><fpage>1014</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">16678584</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtcvs.2005.12.057</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kulig</surname><given-names>K.</given-names></name><name name-style="western"><surname>Boland</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Erickson-Johnson</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Wampfler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jatoi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deschamps</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fortner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stoddard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>F.</given-names></name><name name-style="western"><surname>Molina</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aubry</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>E.S.</given-names></name></person-group><article-title>Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma</article-title><source>J. Thorac. Oncol.</source><volume>7</volume><issue>1</issue><year>2012</year><fpage>90</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">22134072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JTO.0b013e31823c5c32</pub-id><pub-id pub-id-type="pmcid">PMC3931519</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="book" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Travis</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Brambilla</surname><given-names>E.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Marx</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>A.G.</given-names></name></person-group><part-title>WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart</part-title><year>2015</year><publisher-name>IARC Press</publisher-name><publisher-loc>Lyon, France</publisher-loc><fpage>412</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JTO.0000000000000663</pub-id><pub-id pub-id-type="pmid">26291007</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Bubendorf</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buttner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Al-Dayel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dietel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elmberger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lopez-Rios</surname><given-names>F.</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pauwels</surname><given-names>P.</given-names></name><name name-style="western"><surname>Penault-Llorca</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ryska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thunnissen</surname><given-names>E.</given-names></name></person-group><article-title>Testing for ROS1 in non-small cell lung cancer: a review with recommendations</article-title><source>Virchows Arch.</source><volume>469</volume><issue>5</issue><year>2016</year><fpage>489</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">27535289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00428-016-2000-3</pub-id><pub-id pub-id-type="pmcid">PMC5082594</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Goldstraw</surname><given-names>P.</given-names></name><name name-style="western"><surname>Crowley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chansky</surname><given-names>K.</given-names></name><name name-style="western"><surname>Giroux</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Groome</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Rami-Porta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Postmus</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Rusch</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sobin</surname><given-names>L.</given-names></name><collab>C. International Association for the Study of Lung Cancer International Staging, I. Participating</collab></person-group><article-title>The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours</article-title><source>J. Thorac. Oncol.</source><volume>2</volume><issue>8</issue><year>2007</year><fpage>706</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">17762336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JTO.0b013e31812f3c1a</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><article-title>Clinical staging system for carcinoma of the lung</article-title><source>CA A Cancer J. Clin.</source><volume>24</volume><issue>2</issue><year>1974</year><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/canjclin.24.2.87</pub-id><pub-id pub-id-type="pmid">4362505</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Eisenhauer</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Therasse</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bogaerts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Sargent</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dancey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arbuck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gwyther</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rubinstein</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shankar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dodd</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lacombe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Verweij</surname><given-names>J.</given-names></name></person-group><article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title><source>Eur. J. Cancer</source><volume>45</volume><issue>2</issue><year>2009</year><fpage>228</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">19097774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2008.10.026</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="book" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Rosner</surname><given-names>B.</given-names></name></person-group><part-title>Fundamentals of Biostatistics</part-title><edition>eighth ed.</edition><year>2016</year><publisher-name>Cengage Learning</publisher-name><publisher-loc>Boston, MA</publisher-loc></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="book" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Kleinbaum</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>M.</given-names></name></person-group><part-title>Survival Analysis. A Self-Learning Text</part-title><edition>third ed.</edition><year>2012</year><publisher-name>Springer-Verlag</publisher-name><publisher-loc>New York, NY</publisher-loc></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Black</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Khurshid</surname><given-names>H.</given-names></name></person-group><article-title>NSCLC: an update of driver mutations, their role in pathogenesis and clinical significance</article-title><source>R. I. Med. J.</source><volume>98</volume><issue>10</issue><year>2013</year><fpage>25</fpage><lpage>28</lpage><comment>2015</comment><pub-id pub-id-type="pmid">26422542</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="book" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Therneau Tm</surname><given-names>G.P.</given-names></name></person-group><part-title>Modelling Survival Model: Extending the Cox Model</part-title><year>2000</year></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Clav&#233;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gimeno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mu&#241;oz-M&#225;rmol</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reguart</surname><given-names>N.</given-names></name><name name-style="western"><surname>Carcereny</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pijuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Men&#233;ndez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taus</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Mate</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Albanell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Espinet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arriola</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salido</surname><given-names>M.</given-names></name></person-group><article-title>ROS1 copy number alterations are frequent in non-small cell lung cancer</article-title><source>Oncotarget</source><volume>7</volume><issue>7</issue><year>2016</year><fpage>8019</fpage><lpage>8028</lpage><pub-id pub-id-type="pmid">26783962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.6921</pub-id><pub-id pub-id-type="pmcid">PMC4884972</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Dugay</surname><given-names>F.</given-names></name><name name-style="western"><surname>Llamas-Gutierrez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gournay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Medane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mazet</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chiforeanu</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lamy</surname><given-names>R.</given-names></name><name name-style="western"><surname>L&#233;na</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rioux-Leclercq</surname><given-names>N.</given-names></name><name name-style="western"><surname>Belaud-Rotureau</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cabillic</surname><given-names>F.</given-names></name></person-group><article-title>Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations</article-title><source>Oncotarget</source><volume>8</volume><issue>32</issue><year>2017</year><fpage>53336</fpage><lpage>53351</lpage><pub-id pub-id-type="pmid">28881815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.18408</pub-id><pub-id pub-id-type="pmcid">PMC5581114</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Singal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Agarwala</surname><given-names>V.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>G.</given-names></name><name name-style="western"><surname>Backenroth</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gossai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frampton</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Lehnert</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Bourque</surname><given-names>D.</given-names></name><name name-style="western"><surname>O'Connell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bowser</surname><given-names>B.</given-names></name><name name-style="western"><surname>Caron</surname><given-names>T.</given-names></name><name name-style="western"><surname>Baydur</surname><given-names>E.</given-names></name><name name-style="western"><surname>Seidl-Rathkopf</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ivanov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alpha-Cobb</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guria</surname><given-names>A.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nunnally</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jaskiw</surname><given-names>A.</given-names></name><name name-style="western"><surname>Feuchtbaum</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nussbaum</surname><given-names>N.</given-names></name><name name-style="western"><surname>Abernethy</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>V.A.</given-names></name></person-group><article-title>Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database</article-title><source>JAMA</source><volume>321</volume><issue>14</issue><year>2019</year><fpage>1391</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">30964529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.3241</pub-id><pub-id pub-id-type="pmcid">PMC6459115</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Cornelius</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Jamal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Loretan</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Neff</surname><given-names>L.J.</given-names></name></person-group><article-title>Tobacco product use among adults - United States, 2019</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><volume>69</volume><issue>46</issue><year>2020</year><fpage>1736</fpage><lpage>1742</lpage><pub-id pub-id-type="pmid">33211681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6946a4</pub-id><pub-id pub-id-type="pmcid">PMC7676638</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Gainor</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Rizvi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jimenez Aguilar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Skoulidis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yeap</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Naidoo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khosrowjerdi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mooradian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lydon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Illei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ricciuti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nishino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Grishman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Little</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Arbour</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sauter</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Mino-Kenudson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heymach</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Digumarthy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Awad</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Hellmann</surname><given-names>M.D.</given-names></name></person-group><article-title>Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression &#8805;50</article-title><source>Ann. Oncol.</source><volume>31</volume><issue>3</issue><year>2020</year><fpage>404</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">32067682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2019.11.015</pub-id><pub-id pub-id-type="pmcid">PMC7545963</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Kendzia</surname><given-names>B.</given-names></name><name name-style="western"><surname>Behrens</surname><given-names>T.</given-names></name><name name-style="western"><surname>J&#246;ckel</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Siemiatycki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kromhout</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Gelder</surname><given-names>R.</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Br&#252;ske</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wichmann</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>St&#252;cker</surname><given-names>I.</given-names></name><name name-style="western"><surname>Guida</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tard&#243;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Merletti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mirabelli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Richiardi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pohlabeln</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ahrens</surname><given-names>W.</given-names></name><name name-style="western"><surname>Landi</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Caporaso</surname><given-names>N.</given-names></name><name name-style="western"><surname>Consonni</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zaridze</surname><given-names>D.</given-names></name><name name-style="western"><surname>Szeszenia-Dabrowska</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lissowska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gustavsson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Marcus</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fabianova</surname><given-names>E.</given-names></name><name name-style="western"><surname>t Mannetje</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tse</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>I.T.</given-names></name><name name-style="western"><surname>Rudnai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bencko</surname><given-names>V.</given-names></name><name name-style="western"><surname>Janout</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mates</surname><given-names>D.</given-names></name><name name-style="western"><surname>Foretova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Forastiere</surname><given-names>F.</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Demers</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bueno-de-Mesquita</surname><given-names>B.</given-names></name><name name-style="western"><surname>Boffetta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sch&#252;z</surname><given-names>J.</given-names></name><name name-style="western"><surname>Straif</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pesch</surname><given-names>B.</given-names></name><name name-style="western"><surname>Br&#252;ning</surname><given-names>T.</given-names></name></person-group><article-title>Welding and lung cancer in a pooled analysis of case-control studies</article-title><source>Am. J. Epidemiol.</source><volume>178</volume><issue>10</issue><year>2013</year><fpage>1513</fpage><lpage>1525</lpage><pub-id pub-id-type="pmid">24052544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwt201</pub-id><pub-id pub-id-type="pmcid">PMC3888276</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Gu&#233;rin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sasane</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Macalalad</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Galebach</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kageleiry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Culver</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>E.Q.</given-names></name><name name-style="western"><surname>Wakelee</surname><given-names>H.</given-names></name></person-group><article-title>ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer</article-title><source>Cancer Epidemiol</source><volume>39</volume><issue>3</issue><year>2015</year><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">25914136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canep.2015.04.005</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Amos</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Pinney</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kupert</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Andrade</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Fain</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Gazdar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Minna</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wiest</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rothschild</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>D.</given-names></name><name name-style="western"><surname>You</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coons</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gaba</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bailey-Wilson</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.W.</given-names></name></person-group><article-title>A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers</article-title><source>Cancer Res.</source><volume>70</volume><issue>6</issue><year>2010</year><fpage>2359</fpage><lpage>2367</lpage><pub-id pub-id-type="pmid">20215501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-09-3096</pub-id><pub-id pub-id-type="pmcid">PMC2855643</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Faeh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haile</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Bopp</surname><given-names>M.</given-names></name></person-group><article-title>BMI-mortality association: shape independent of smoking status but different for chronic lung disease and lung cancer</article-title><source>Int. J. Chronic Obstr. Pulm. Dis.</source><volume>13</volume><year>2018</year><fpage>1851</fpage><lpage>1855</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/COPD.S157629</pub-id><pub-id pub-id-type="pmcid">PMC5995287</pub-id><pub-id pub-id-type="pmid">29922051</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Ostrow</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Michailidi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guerrero-Preston</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hoque</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rom</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sidransky</surname><given-names>D.</given-names></name></person-group><article-title>Cigarette smoke induces methylation of the tumor suppressor gene NISCH</article-title><source>Epigenetics</source><volume>8</volume><issue>4</issue><year>2013</year><fpage>383</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">23503203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/epi.24195</pub-id><pub-id pub-id-type="pmcid">PMC3674047</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sonobe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshizawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Date</surname><given-names>H.</given-names></name></person-group><article-title>Detection of ALK fusion in lung cancer using fluorescence in situ hybridization</article-title><source>Asian Cardiovasc. Thorac. Ann.</source><volume>20</volume><issue>4</issue><year>2012</year><fpage>426</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">22879549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0218492312440700</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>R.Q.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.L.</given-names></name></person-group><article-title>A clinical model to estimate the pretest probability of lung cancer, based on 1198 pedigrees in China</article-title><source>J. Thorac. Oncol.</source><volume>7</volume><issue>10</issue><year>2012</year><fpage>1534</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">22982654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JTO.0b013e3182641b82</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Shome</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Engelbrektson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Song</surname><given-names>L.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murugan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y.</given-names></name><name name-style="western"><surname>LaBaer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J.</given-names></name></person-group><article-title>Comparative microbiomics analysis of antimicrobial antibody response between patients with lung cancer and control subjects with benign pulmonary nodules</article-title><source>Cancer Epidemiol. Biomarkers Prev.</source><volume>32</volume><issue>4</issue><year>2023</year><fpage>496</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">36066883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-22-0384</pub-id><pub-id pub-id-type="pmcid">PMC10494706</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Gejman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mu&#241;oz-Medel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nervi</surname><given-names>B.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ib&#225;&#241;ez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>J.</given-names></name><name name-style="western"><surname>Madrid</surname><given-names>J.</given-names></name><name name-style="western"><surname>Briones</surname><given-names>J.</given-names></name><name name-style="western"><surname>P&#233;rez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Garrido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Galindo</surname><given-names>H.</given-names></name></person-group><article-title>Prevalence of EGFR mutations and clinico-pathological characteristics of Chilean lung cancer patients</article-title><source>Asian Pac. J. Cancer Prev. APJCP</source><volume>20</volume><issue>1</issue><year>2019</year><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">30677862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31557/APJCP.2019.20.1.1</pub-id><pub-id pub-id-type="pmcid">PMC6485557</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Ishibe</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wiencke</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>Z.F.</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kelsey</surname><given-names>K.T.</given-names></name></person-group><article-title>Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans</article-title><source>Cancer Epidemiol. Biomarkers Prev.</source><volume>6</volume><issue>12</issue><year>1997</year><fpage>1075</fpage><lpage>1080</lpage><pub-id pub-id-type="pmid">9419406</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Nawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fukui</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sagawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ichimura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mizoue</surname><given-names>T.</given-names></name></person-group><article-title>A population-based cohort study to evaluate the effectiveness of lung cancer screening using low-dose CT in Hitachi city, Japan</article-title><source>Jpn. J. Clin. Oncol.</source><volume>49</volume><issue>2</issue><year>2019</year><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">30541133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jjco/hyy185</pub-id><pub-id pub-id-type="pmcid">PMC6366936</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Litvak</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Paik</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Sima</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Hellmann</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Arcila</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ladanyi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rudin</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kris</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Riely</surname><given-names>G.J.</given-names></name></person-group><article-title>Clinical characteristics and course of 63 patients with BRAF mutant lung cancers</article-title><source>J. Thorac. Oncol.</source><volume>9</volume><issue>11</issue><year>2014</year><fpage>1669</fpage><lpage>1674</lpage><pub-id pub-id-type="pmid">25436800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JTO.0000000000000344</pub-id><pub-id pub-id-type="pmcid">PMC4251710</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Fallet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cadranel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Doubre</surname><given-names>H.</given-names></name><name name-style="western"><surname>Toper</surname><given-names>C.</given-names></name><name name-style="western"><surname>Monnet</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chinet</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oliviero</surname><given-names>G.</given-names></name><name name-style="western"><surname>Foulon</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Cremoux</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vieira</surname><given-names>T.</given-names></name><name name-style="western"><surname>Antoine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wislez</surname><given-names>M.</given-names></name></person-group><article-title>Prospective screening for ALK: clinical features and outcome according to ALK status</article-title><source>Eur. J. Cancer</source><volume>50</volume><issue>7</issue><year>2014</year><fpage>1239</fpage><lpage>1246</lpage><pub-id pub-id-type="pmid">24589437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2014.02.001</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Pavanello</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fedeli</surname><given-names>U.</given-names></name><name name-style="western"><surname>Mastrangelo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rota</surname><given-names>F.</given-names></name><name name-style="western"><surname>Overvad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raaschou-Nielsen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tj&#248;nneland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>U.</given-names></name></person-group><article-title>Role of CYP1A2 polymorphisms on lung cancer risk in a prospective study</article-title><source>Cancer Genet</source><volume>205</volume><issue>6</issue><year>2012</year><fpage>278</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">22749033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cancergen.2012.02.004</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Ruano-Ravina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cameselle-Lago</surname><given-names>C.</given-names></name><name name-style="western"><surname>Torres-Dur&#225;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pando-Sandoval</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dacal-Quintas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vald&#233;s-Cuadrado</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Hern&#225;ndez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Consuegra-Vanegas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tenes-May&#233;n</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Varela-Lema</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Villar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barros-Dios</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>P&#233;rez-R&#237;os</surname><given-names>M.</given-names></name></person-group><article-title>Indoor radon exposure and copd, synergic association? A multicentric, hospital-based case-control study in a radon-prone area</article-title><source>Arch. Bronconeumol.</source><volume>57</volume><issue>10</issue><year>2021</year><fpage>630</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">35699045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arbr.2020.11.020</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>B.</given-names></name></person-group><article-title>DNA repair gene polymorphisms in relation to non-small cell lung cancer survival</article-title><source>Cell. Physiol. Biochem.</source><volume>36</volume><issue>4</issue><year>2015</year><fpage>1419</fpage><lpage>1429</lpage><pub-id pub-id-type="pmid">26159902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000430307</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chirieac</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wain</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heist</surname><given-names>R.</given-names></name><name name-style="western"><surname>Skaug</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zienolddiny</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haugen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Christiani</surname><given-names>D.C.</given-names></name></person-group><article-title>Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>108</volume><issue>39</issue><year>2011</year><fpage>16345</fpage><lpage>16350</lpage><pub-id pub-id-type="pmid">21911369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1102769108</pub-id><pub-id pub-id-type="pmcid">PMC3182687</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toyooka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Endo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maniwa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fukuchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chida</surname><given-names>M.</given-names></name></person-group><article-title>Preoperative cumulative smoking dose on lung cancer surgery in a Japanese nationwide database</article-title><source>Ann. Thorac. Surg.</source><volume>113</volume><issue>1</issue><year>2022</year><fpage>237</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">33600791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.athoracsur.2021.01.055</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Fois</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Paliogiannis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zinellu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fois</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Cossu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Palmieri</surname><given-names>G.</given-names></name></person-group><article-title>Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer</article-title><source>Int. J. Mol. Sci.</source><volume>22</volume><issue>2</issue><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22020612</pub-id><pub-id pub-id-type="pmcid">PMC7827915</pub-id><pub-id pub-id-type="pmid">33435440</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Conde</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rojo</surname><given-names>F.</given-names></name><name name-style="western"><surname>G&#243;mez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Enguita</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Abdulkader</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lozano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Manche&#241;o</surname><given-names>N.</given-names></name><name name-style="western"><surname>Salas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Salido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salido-Ruiz</surname><given-names>E.</given-names></name><name name-style="western"><surname>de &#193;lava</surname><given-names>E.</given-names></name></person-group><article-title>Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing</article-title><source>J. Clin. Pathol.</source><volume>75</volume><issue>3</issue><year>2022</year><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">33875457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jclinpath-2021-207490</pub-id><pub-id pub-id-type="pmcid">PMC8862096</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Kerr</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Bubendorf</surname><given-names>L.</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>T.</given-names></name><name name-style="western"><surname>Novello</surname><given-names>S.</given-names></name><name name-style="western"><surname>O'Byrne</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stahel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>Panel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Panel</surname><given-names>M.</given-names></name></person-group><article-title>Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer</article-title><source>Ann. Oncol.</source><volume>25</volume><issue>9</issue><year>2014</year><fpage>1681</fpage><lpage>1690</lpage><pub-id pub-id-type="pmid">24718890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdu145</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Wiesweg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eberhardt</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ting</surname><given-names>S.</given-names></name><name name-style="western"><surname>Savvidou</surname><given-names>N.</given-names></name><name name-style="western"><surname>Skiba</surname><given-names>C.</given-names></name><name name-style="western"><surname>Herold</surname><given-names>T.</given-names></name><name name-style="western"><surname>Christoph</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Meiler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Worm</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kasper</surname><given-names>S.</given-names></name><name name-style="western"><surname>Theegarten</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hense</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hager</surname><given-names>T.</given-names></name><name name-style="western"><surname>Darwiche</surname><given-names>K.</given-names></name><name name-style="western"><surname>Oezkan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Aigner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Welter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuhl</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stuschke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>M.</given-names></name></person-group><article-title>High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer</article-title><source>J. Thorac. Oncol.</source><volume>12</volume><issue>1</issue><year>2017</year><fpage>54</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">27575422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2016.08.137</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Su</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name></person-group><article-title>ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases</article-title><source>J. Thorac. Dis.</source><volume>9</volume><issue>10</issue><year>2017</year><fpage>3919</fpage><lpage>3926</lpage><pub-id pub-id-type="pmid">29268402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/jtd.2017.09.79</pub-id><pub-id pub-id-type="pmcid">PMC5723822</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Franchina</surname><given-names>T.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ricciardi</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Liguori</surname><given-names>G.</given-names></name><name name-style="western"><surname>Herberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Normanno</surname><given-names>N.</given-names></name><name name-style="western"><surname>Adamo</surname><given-names>V.</given-names></name></person-group><article-title>Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site</article-title><source>Cancer Biol. Ther.</source><year>2016</year><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15384047.2016.1219822</pub-id><pub-id pub-id-type="pmcid">PMC5079394</pub-id><pub-id pub-id-type="pmid">27611848</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Preusser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Streubel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Birner</surname><given-names>P.</given-names></name></person-group><article-title>ROS1 translocations and amplifications in lung cancer brain metastases</article-title><source>J. Neuro Oncol.</source><volume>118</volume><issue>2</issue><year>2014</year><fpage>425</fpage><lpage>426</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-014-1446-x</pub-id><pub-id pub-id-type="pmid">24760415</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Ettinger</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Aisner</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Akerley</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bauman</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Bharat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Chirieac</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>DeCamp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dilling</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Dowell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Durm</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Gettinger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grotz</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Gubens</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hegde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lackner</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Lanuti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Loo</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Lovly</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Maldonado</surname><given-names>F.</given-names></name><name name-style="western"><surname>Massarelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Morgensztern</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Otterson</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>T.</given-names></name><name name-style="western"><surname>Polanco</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Riely</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Riess</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schild</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tanvetyanon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yanagawa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Yau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>M.</given-names></name></person-group><article-title>NCCN Guidelines&#174; insights: non-small cell lung cancer, version 2.2023</article-title><source>J. Natl. Compr. Cancer Netw.</source><volume>21</volume><issue>4</issue><year>2023</year><fpage>340</fpage><lpage>350</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2023.0020</pub-id><pub-id pub-id-type="pmid">37015337</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Riely</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Bang</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Varella-Garcia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iafrate</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Usari</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Wilner</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S.I.</given-names></name></person-group><article-title>Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001</article-title><source>Ann. Oncol.</source><volume>30</volume><issue>7</issue><year>2019</year><fpage>1121</fpage><lpage>1126</lpage><pub-id pub-id-type="pmid">30980071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdz131</pub-id><pub-id pub-id-type="pmcid">PMC6637370</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0210">The following is the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgement</title><p id="p0205">The study was funded by <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100007048</institution-id><institution>Mayo Foundation, United States</institution></institution-wrap></funding-source> (NIH-R01-84354), and Pfizer Inc. Yanmei Peng was funded by Chinese Scholarship Council (202106557002). The authors would like to acknowledge Shawn M Stoddard contributed to data collection and quality control and Willam R. Sukov assisted with sample testing; they were both full-time employees of Mayo Clinic at the time of study initiation. Hannah Le who was the Global Lung Value &amp; Health Lead in HEOR and Nada Rifi who was lung medical lead at Pfizer helped review the manuscript.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0215">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.heliyon.2024.e28285" id="intref0010">https://doi.org/10.1016/j.heliyon.2024.e28285</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>